Study Protocol of the Bladder Adjuvant RadioTherapy (BART) Trial: A Randomised Phase III Trial of Adjuvant Radiotherapy Following Cystectomy in Bladder Cancer.

To assess the efficacy and safety of adjuvant radiotherapy in patients with high-risk muscle-invasive bladder cancer (MIBC) following radical cystectomy (RC) and chemotherapy.

The BART (Bladder Adjuvant RadioTherapy) trial is an ongoing multicentric, randomised, phase III trial comparing the efficacy and safety of adjuvant radiotherapy versus observation in patients with high-risk MIBC. The key eligibility criteria include ≥pT3, node-positive (pN+), positive margins and/or nodal yield <10, or, neoadjuvant chemotherapy for cT3/T4/N+ disease. In total, 153 patients will be accrued and randomised, in a 1:1 ratio, to either observation (standard arm) or adjuvant radiotherapy (test arm) following surgery and chemotherapy. Stratification parameters include nodal status (N+ versus N0) and chemotherapy (neoadjuvant chemotherapy versus adjuvant chemotherapy versus no chemotherapy). For patients in the test arm, adjuvant radiotherapy to cystectomy bed and pelvic nodes is planned with intensity-modulated radiotherapy to a dose of 50.4 Gy in 28 fractions using daily image guidance. All patients will follow-up with 3-monthly clinical review and urine cytology for 2 years and subsequently 6 monthly until 5 years, with contrast-enhanced computed tomography abdomen pelvis 6 monthly for 2 years and annually until 5 years. Physician-scored toxicity using Common Terminology Criteria for Adverse Events version 5.0 and patient-reported quality of life using the Functional Assessment of Cancer Therapy - Colorectal questionnaire is recorded pre-treatment and at follow-up.

The primary endpoint is 2-year locoregional recurrence-free survival. The sample size calculation was based on the estimated improvement in 2-year locoregional recurrence-free survival from 70% in the standard arm to 85% in the test arm (hazard ratio 0.45) using 80% statistical power and a two-sided alpha error of 0.05. Secondary endpoints include disease-free survival, overall survival, acute and late toxicity, patterns of failure and quality of life.

The BART trial aims to evaluate whether contemporary radiotherapy after standard-of-care surgery and chemotherapy reduces pelvic recurrences safely and also potentially affects survival in high-risk MIBC.

Clinical oncology (Royal College of Radiologists (Great Britain)). 2023 May 05 [Epub ahead of print]

V Murthy, P Maitre, M Singh, M Pal, A Arora, L Pujari, A Kapoor, H Pandey, R Sharma, D Gudipudi, A Joshi, K Prabhash, V Noronha, S Menon, P Mehta, G Bakshi, G Prakash

Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India. Electronic address: ., Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of Radiation Oncology, HBCH & MPMMMC, Varanasi, India., Department of Medical Oncology, HBCH & MPMMMC, Varanasi, India., Department of Surgical Oncology, HBCH & MPMMMC, Varanasi, India., Department of Uro-Oncology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India., Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.